ATE525394T1 - Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung - Google Patents

Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung

Info

Publication number
ATE525394T1
ATE525394T1 AT08758607T AT08758607T ATE525394T1 AT E525394 T1 ATE525394 T1 AT E525394T1 AT 08758607 T AT08758607 T AT 08758607T AT 08758607 T AT08758607 T AT 08758607T AT E525394 T1 ATE525394 T1 AT E525394T1
Authority
AT
Austria
Prior art keywords
vip
treatment
vasoactive intestinal
intestinal peptide
peptides
Prior art date
Application number
AT08758607T
Other languages
English (en)
Inventor
Michael Roth-Chiarello
Original Assignee
Res Internat Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Internat Sarl filed Critical Res Internat Sarl
Application granted granted Critical
Publication of ATE525394T1 publication Critical patent/ATE525394T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT08758607T 2007-05-21 2008-05-19 Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung ATE525394T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07010033 2007-05-21
PCT/EP2008/003989 WO2008141786A2 (en) 2007-05-21 2008-05-19 Peptides having the biological activity of vasoactive intestinal peptide (vip) and their use for the treatment of lung diseases

Publications (1)

Publication Number Publication Date
ATE525394T1 true ATE525394T1 (de) 2011-10-15

Family

ID=39828222

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08758607T ATE525394T1 (de) 2007-05-21 2008-05-19 Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung

Country Status (6)

Country Link
US (1) US8329640B2 (de)
EP (1) EP2152741B1 (de)
AT (1) ATE525394T1 (de)
CA (1) CA2687602C (de)
ES (1) ES2373824T3 (de)
WO (1) WO2008141786A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
EP3412300A1 (de) 2008-06-27 2018-12-12 Duke University Therapeutika mit elastinähnlichen peptiden
DK3311828T3 (da) 2009-08-14 2021-06-28 Phasebio Pharmaceuticals Inc Modificerede vasoaktive tarmpeptider
WO2012170524A1 (en) 2011-06-06 2012-12-13 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
WO2014100578A1 (en) * 2012-12-20 2014-06-26 The Brigham And Women's Hospital, Inc. Peptides useful for modulating histone demethylase function
JP6346202B2 (ja) * 2013-02-15 2018-06-20 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 生体液中の脱落または循環腫瘍細胞を検出するための方法
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
CA2976038A1 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders
EP3583933A1 (de) 2018-06-20 2019-12-25 Albert-Ludwigs-Universität Freiburg Verabreichung von aviptadil durch inhalation zur behandlung von chronischer berylliumkrankheit
CA3138891A1 (en) * 2019-05-07 2020-11-12 Advita Lifescience Gmbh Vasoactive intestinal peptide (vip) for use in the treatment of drug-induced pneumonitis
CA3214539A1 (en) * 2021-04-20 2022-10-27 Dorian Bevec Use of aviptadil alone or in combination with alpha lipoic acid as a therapeutic medicament for post-viral infection syndrome
JP2025503688A (ja) * 2022-01-12 2025-02-04 マンカインド コーポレイション 医薬組成物及び方法
DE102024001175A1 (de) 2024-04-04 2025-10-09 ReViSan Healthcare GmbH Zubereitung zur Behandlung von entzündlichen Erkrankungen der Atemwege.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002220720B2 (en) * 2000-11-28 2006-09-14 Mondobiotech Ag Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension

Also Published As

Publication number Publication date
EP2152741B1 (de) 2011-09-21
CA2687602C (en) 2014-07-15
WO2008141786A3 (en) 2009-02-05
CA2687602A1 (en) 2008-11-27
ES2373824T3 (es) 2012-02-09
EP2152741A2 (de) 2010-02-17
WO2008141786A2 (en) 2008-11-27
US8329640B2 (en) 2012-12-11
US20100256044A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
ATE525394T1 (de) Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung
ATE430569T1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
UY29506A1 (es) Nuevas formas cristalinas de bromuro de tiotropio
BRPI0819932A2 (pt) composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável.
NO20083793L (no) Antistoffer mot amyloid-beta peptid
JP2017000143A5 (de)
EA200901300A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
ATE516285T1 (de) Dihydropyridinonderivate
JP2008514618A5 (de)
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
EA201390739A1 (ru) Способ лечения fgf21-ассоциированных расстройств
DE602005017636D1 (de) Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen
EA201100423A1 (ru) Новые бензамиды, их получение и их применение в качестве лекарственных средств
DE602008005155D1 (de) Glp-1-fc fusionsprotein-formulierung
CY1115316T1 (el) Πεπτιδια για τη θεραπευτικη αγωγη βητα-αμυλοειδωσεων
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
ECSP22016558A (es) Proteínas de fusión terapéuticas
EP2411003A4 (de) Verwendung von artemisininderivaten zur behandlung von asthma und chronisch obstruktiver lungenerkrankung (copd)
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
EP3536794A3 (de) Peptide mit spezifität für die lunge
ATE457736T1 (de) Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
EP4479062A4 (de) Formen, geeignet zur oralen verabreichung de l'agoniste de trss, vk2809, zur durchführung von hépartiques, et procédeparation de celles
CL2008000973A1 (es) Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
ATE482709T1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2152741

Country of ref document: EP